Global Restless Legs Syndrome Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Restless Legs Syndrome market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Restless legs syndrome (RLS) is a neurological disease. RLS is also called as Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible desire to move their feet. The continual movement of the legs leads to pain in the limbs, which leads to the unusual sleep pattern of patients.
Global key players of Restless Legs Syndrome include Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, etc.
Boehringer Ingelheim GmbH is the largest manufacturers of Restless Legs Syndrome in the world, has a share about 70%.
This report is a detailed and comprehensive analysis for global Restless Legs Syndrome market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Restless Legs Syndrome market size and forecasts, in consumption value ($ Million), 2021-2032
Global Restless Legs Syndrome market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Restless Legs Syndrome market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Restless Legs Syndrome market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Restless Legs Syndrome
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Restless Legs Syndrome market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., Omeros Corporation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Restless Legs Syndrome market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Restless Legs Syndrome product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Restless Legs Syndrome, with revenue, gross margin, and global market share of Restless Legs Syndrome from 2021 to 2026.
Chapter 3, the Restless Legs Syndrome competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Restless Legs Syndrome market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Restless Legs Syndrome.
Chapter 13, to describe Restless Legs Syndrome research findings and conclusion.
Restless legs syndrome (RLS) is a neurological disease. RLS is also called as Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible desire to move their feet. The continual movement of the legs leads to pain in the limbs, which leads to the unusual sleep pattern of patients.
Global key players of Restless Legs Syndrome include Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, etc.
Boehringer Ingelheim GmbH is the largest manufacturers of Restless Legs Syndrome in the world, has a share about 70%.
This report is a detailed and comprehensive analysis for global Restless Legs Syndrome market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Restless Legs Syndrome market size and forecasts, in consumption value ($ Million), 2021-2032
Global Restless Legs Syndrome market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Restless Legs Syndrome market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Restless Legs Syndrome market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Restless Legs Syndrome
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Restless Legs Syndrome market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., Omeros Corporation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Restless Legs Syndrome market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Pharmacological Therapy
- Non-Pharmacological Therapy
- Below 35 Years Old
- From 35 to 50 Years Old
- Above 50 Years Old
- Boehringer Ingelheim GmbH
- UCB SA
- Astellas
- Arbor Pharmaceuticals
- GlaxoSmithKline plc.
- Ligand Pharmaceuticals Incorporated
- axxonis Pharma AG
- Kyowa Hakko Kirin Co.
- Jazz Pharmaceuticals, Inc.
- Omeros Corporation
- Manhattan Pharmaceuticals
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Restless Legs Syndrome product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Restless Legs Syndrome, with revenue, gross margin, and global market share of Restless Legs Syndrome from 2021 to 2026.
Chapter 3, the Restless Legs Syndrome competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Restless Legs Syndrome market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Restless Legs Syndrome.
Chapter 13, to describe Restless Legs Syndrome research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Restless Legs Syndrome by Type
1.3.1 Overview: Global Restless Legs Syndrome Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Restless Legs Syndrome Consumption Value Market Share by Type in 2025
1.3.3 Pharmacological Therapy
1.3.4 Non-Pharmacological Therapy
1.4 Global Restless Legs Syndrome Market by Application
1.4.1 Overview: Global Restless Legs Syndrome Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Below 35 Years Old
1.4.3 From 35 to 50 Years Old
1.4.4 Above 50 Years Old
1.5 Global Restless Legs Syndrome Market Size & Forecast
1.6 Global Restless Legs Syndrome Market Size and Forecast by Region
1.6.1 Global Restless Legs Syndrome Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Restless Legs Syndrome Market Size by Region, (2021-2032)
1.6.3 North America Restless Legs Syndrome Market Size and Prospect (2021-2032)
1.6.4 Europe Restless Legs Syndrome Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Restless Legs Syndrome Market Size and Prospect (2021-2032)
1.6.6 South America Restless Legs Syndrome Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Restless Legs Syndrome Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Boehringer Ingelheim GmbH
2.1.1 Boehringer Ingelheim GmbH Details
2.1.2 Boehringer Ingelheim GmbH Major Business
2.1.3 Boehringer Ingelheim GmbH Restless Legs Syndrome Product and Solutions
2.1.4 Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
2.2 UCB SA
2.2.1 UCB SA Details
2.2.2 UCB SA Major Business
2.2.3 UCB SA Restless Legs Syndrome Product and Solutions
2.2.4 UCB SA Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 UCB SA Recent Developments and Future Plans
2.3 Astellas
2.3.1 Astellas Details
2.3.2 Astellas Major Business
2.3.3 Astellas Restless Legs Syndrome Product and Solutions
2.3.4 Astellas Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Astellas Recent Developments and Future Plans
2.4 Arbor Pharmaceuticals
2.4.1 Arbor Pharmaceuticals Details
2.4.2 Arbor Pharmaceuticals Major Business
2.4.3 Arbor Pharmaceuticals Restless Legs Syndrome Product and Solutions
2.4.4 Arbor Pharmaceuticals Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Arbor Pharmaceuticals Recent Developments and Future Plans
2.5 GlaxoSmithKline plc.
2.5.1 GlaxoSmithKline plc. Details
2.5.2 GlaxoSmithKline plc. Major Business
2.5.3 GlaxoSmithKline plc. Restless Legs Syndrome Product and Solutions
2.5.4 GlaxoSmithKline plc. Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 GlaxoSmithKline plc. Recent Developments and Future Plans
2.6 Ligand Pharmaceuticals Incorporated
2.6.1 Ligand Pharmaceuticals Incorporated Details
2.6.2 Ligand Pharmaceuticals Incorporated Major Business
2.6.3 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product and Solutions
2.6.4 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Ligand Pharmaceuticals Incorporated Recent Developments and Future Plans
2.7 axxonis Pharma AG
2.7.1 axxonis Pharma AG Details
2.7.2 axxonis Pharma AG Major Business
2.7.3 axxonis Pharma AG Restless Legs Syndrome Product and Solutions
2.7.4 axxonis Pharma AG Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 axxonis Pharma AG Recent Developments and Future Plans
2.8 Kyowa Hakko Kirin Co.
2.8.1 Kyowa Hakko Kirin Co. Details
2.8.2 Kyowa Hakko Kirin Co. Major Business
2.8.3 Kyowa Hakko Kirin Co. Restless Legs Syndrome Product and Solutions
2.8.4 Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Kyowa Hakko Kirin Co. Recent Developments and Future Plans
2.9 Jazz Pharmaceuticals, Inc.
2.9.1 Jazz Pharmaceuticals, Inc. Details
2.9.2 Jazz Pharmaceuticals, Inc. Major Business
2.9.3 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product and Solutions
2.9.4 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Jazz Pharmaceuticals, Inc. Recent Developments and Future Plans
2.10 Omeros Corporation
2.10.1 Omeros Corporation Details
2.10.2 Omeros Corporation Major Business
2.10.3 Omeros Corporation Restless Legs Syndrome Product and Solutions
2.10.4 Omeros Corporation Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Omeros Corporation Recent Developments and Future Plans
2.11 Manhattan Pharmaceuticals
2.11.1 Manhattan Pharmaceuticals Details
2.11.2 Manhattan Pharmaceuticals Major Business
2.11.3 Manhattan Pharmaceuticals Restless Legs Syndrome Product and Solutions
2.11.4 Manhattan Pharmaceuticals Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Manhattan Pharmaceuticals Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Restless Legs Syndrome Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Restless Legs Syndrome by Company Revenue
3.2.2 Top 3 Restless Legs Syndrome Players Market Share in 2025
3.2.3 Top 6 Restless Legs Syndrome Players Market Share in 2025
3.3 Restless Legs Syndrome Market: Overall Company Footprint Analysis
3.3.1 Restless Legs Syndrome Market: Region Footprint
3.3.2 Restless Legs Syndrome Market: Company Product Type Footprint
3.3.3 Restless Legs Syndrome Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Restless Legs Syndrome Consumption Value and Market Share by Type (2021-2026)
4.2 Global Restless Legs Syndrome Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Restless Legs Syndrome Consumption Value Market Share by Application (2021-2026)
5.2 Global Restless Legs Syndrome Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Restless Legs Syndrome Consumption Value by Type (2021-2032)
6.2 North America Restless Legs Syndrome Market Size by Application (2021-2032)
6.3 North America Restless Legs Syndrome Market Size by Country
6.3.1 North America Restless Legs Syndrome Consumption Value by Country (2021-2032)
6.3.2 United States Restless Legs Syndrome Market Size and Forecast (2021-2032)
6.3.3 Canada Restless Legs Syndrome Market Size and Forecast (2021-2032)
6.3.4 Mexico Restless Legs Syndrome Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Restless Legs Syndrome Consumption Value by Type (2021-2032)
7.2 Europe Restless Legs Syndrome Consumption Value by Application (2021-2032)
7.3 Europe Restless Legs Syndrome Market Size by Country
7.3.1 Europe Restless Legs Syndrome Consumption Value by Country (2021-2032)
7.3.2 Germany Restless Legs Syndrome Market Size and Forecast (2021-2032)
7.3.3 France Restless Legs Syndrome Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Restless Legs Syndrome Market Size and Forecast (2021-2032)
7.3.5 Russia Restless Legs Syndrome Market Size and Forecast (2021-2032)
7.3.6 Italy Restless Legs Syndrome Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Restless Legs Syndrome Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Restless Legs Syndrome Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Restless Legs Syndrome Market Size by Region
8.3.1 Asia-Pacific Restless Legs Syndrome Consumption Value by Region (2021-2032)
8.3.2 China Restless Legs Syndrome Market Size and Forecast (2021-2032)
8.3.3 Japan Restless Legs Syndrome Market Size and Forecast (2021-2032)
8.3.4 South Korea Restless Legs Syndrome Market Size and Forecast (2021-2032)
8.3.5 India Restless Legs Syndrome Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Restless Legs Syndrome Market Size and Forecast (2021-2032)
8.3.7 Australia Restless Legs Syndrome Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Restless Legs Syndrome Consumption Value by Type (2021-2032)
9.2 South America Restless Legs Syndrome Consumption Value by Application (2021-2032)
9.3 South America Restless Legs Syndrome Market Size by Country
9.3.1 South America Restless Legs Syndrome Consumption Value by Country (2021-2032)
9.3.2 Brazil Restless Legs Syndrome Market Size and Forecast (2021-2032)
9.3.3 Argentina Restless Legs Syndrome Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Restless Legs Syndrome Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Restless Legs Syndrome Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Restless Legs Syndrome Market Size by Country
10.3.1 Middle East & Africa Restless Legs Syndrome Consumption Value by Country (2021-2032)
10.3.2 Turkey Restless Legs Syndrome Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Restless Legs Syndrome Market Size and Forecast (2021-2032)
10.3.4 UAE Restless Legs Syndrome Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Restless Legs Syndrome Market Drivers
11.2 Restless Legs Syndrome Market Restraints
11.3 Restless Legs Syndrome Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Restless Legs Syndrome Industry Chain
12.2 Restless Legs Syndrome Upstream Analysis
12.3 Restless Legs Syndrome Midstream Analysis
12.4 Restless Legs Syndrome Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Restless Legs Syndrome by Type
1.3.1 Overview: Global Restless Legs Syndrome Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Restless Legs Syndrome Consumption Value Market Share by Type in 2025
1.3.3 Pharmacological Therapy
1.3.4 Non-Pharmacological Therapy
1.4 Global Restless Legs Syndrome Market by Application
1.4.1 Overview: Global Restless Legs Syndrome Market Size by Application: 2021 Versus 2025 Versus 2032
1.4.2 Below 35 Years Old
1.4.3 From 35 to 50 Years Old
1.4.4 Above 50 Years Old
1.5 Global Restless Legs Syndrome Market Size & Forecast
1.6 Global Restless Legs Syndrome Market Size and Forecast by Region
1.6.1 Global Restless Legs Syndrome Market Size by Region: 2021 VS 2025 VS 2032
1.6.2 Global Restless Legs Syndrome Market Size by Region, (2021-2032)
1.6.3 North America Restless Legs Syndrome Market Size and Prospect (2021-2032)
1.6.4 Europe Restless Legs Syndrome Market Size and Prospect (2021-2032)
1.6.5 Asia-Pacific Restless Legs Syndrome Market Size and Prospect (2021-2032)
1.6.6 South America Restless Legs Syndrome Market Size and Prospect (2021-2032)
1.6.7 Middle East & Africa Restless Legs Syndrome Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Boehringer Ingelheim GmbH
2.1.1 Boehringer Ingelheim GmbH Details
2.1.2 Boehringer Ingelheim GmbH Major Business
2.1.3 Boehringer Ingelheim GmbH Restless Legs Syndrome Product and Solutions
2.1.4 Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
2.2 UCB SA
2.2.1 UCB SA Details
2.2.2 UCB SA Major Business
2.2.3 UCB SA Restless Legs Syndrome Product and Solutions
2.2.4 UCB SA Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 UCB SA Recent Developments and Future Plans
2.3 Astellas
2.3.1 Astellas Details
2.3.2 Astellas Major Business
2.3.3 Astellas Restless Legs Syndrome Product and Solutions
2.3.4 Astellas Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Astellas Recent Developments and Future Plans
2.4 Arbor Pharmaceuticals
2.4.1 Arbor Pharmaceuticals Details
2.4.2 Arbor Pharmaceuticals Major Business
2.4.3 Arbor Pharmaceuticals Restless Legs Syndrome Product and Solutions
2.4.4 Arbor Pharmaceuticals Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Arbor Pharmaceuticals Recent Developments and Future Plans
2.5 GlaxoSmithKline plc.
2.5.1 GlaxoSmithKline plc. Details
2.5.2 GlaxoSmithKline plc. Major Business
2.5.3 GlaxoSmithKline plc. Restless Legs Syndrome Product and Solutions
2.5.4 GlaxoSmithKline plc. Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 GlaxoSmithKline plc. Recent Developments and Future Plans
2.6 Ligand Pharmaceuticals Incorporated
2.6.1 Ligand Pharmaceuticals Incorporated Details
2.6.2 Ligand Pharmaceuticals Incorporated Major Business
2.6.3 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product and Solutions
2.6.4 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Ligand Pharmaceuticals Incorporated Recent Developments and Future Plans
2.7 axxonis Pharma AG
2.7.1 axxonis Pharma AG Details
2.7.2 axxonis Pharma AG Major Business
2.7.3 axxonis Pharma AG Restless Legs Syndrome Product and Solutions
2.7.4 axxonis Pharma AG Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 axxonis Pharma AG Recent Developments and Future Plans
2.8 Kyowa Hakko Kirin Co.
2.8.1 Kyowa Hakko Kirin Co. Details
2.8.2 Kyowa Hakko Kirin Co. Major Business
2.8.3 Kyowa Hakko Kirin Co. Restless Legs Syndrome Product and Solutions
2.8.4 Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Kyowa Hakko Kirin Co. Recent Developments and Future Plans
2.9 Jazz Pharmaceuticals, Inc.
2.9.1 Jazz Pharmaceuticals, Inc. Details
2.9.2 Jazz Pharmaceuticals, Inc. Major Business
2.9.3 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product and Solutions
2.9.4 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Jazz Pharmaceuticals, Inc. Recent Developments and Future Plans
2.10 Omeros Corporation
2.10.1 Omeros Corporation Details
2.10.2 Omeros Corporation Major Business
2.10.3 Omeros Corporation Restless Legs Syndrome Product and Solutions
2.10.4 Omeros Corporation Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Omeros Corporation Recent Developments and Future Plans
2.11 Manhattan Pharmaceuticals
2.11.1 Manhattan Pharmaceuticals Details
2.11.2 Manhattan Pharmaceuticals Major Business
2.11.3 Manhattan Pharmaceuticals Restless Legs Syndrome Product and Solutions
2.11.4 Manhattan Pharmaceuticals Restless Legs Syndrome Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Manhattan Pharmaceuticals Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Restless Legs Syndrome Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Restless Legs Syndrome by Company Revenue
3.2.2 Top 3 Restless Legs Syndrome Players Market Share in 2025
3.2.3 Top 6 Restless Legs Syndrome Players Market Share in 2025
3.3 Restless Legs Syndrome Market: Overall Company Footprint Analysis
3.3.1 Restless Legs Syndrome Market: Region Footprint
3.3.2 Restless Legs Syndrome Market: Company Product Type Footprint
3.3.3 Restless Legs Syndrome Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Restless Legs Syndrome Consumption Value and Market Share by Type (2021-2026)
4.2 Global Restless Legs Syndrome Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Restless Legs Syndrome Consumption Value Market Share by Application (2021-2026)
5.2 Global Restless Legs Syndrome Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Restless Legs Syndrome Consumption Value by Type (2021-2032)
6.2 North America Restless Legs Syndrome Market Size by Application (2021-2032)
6.3 North America Restless Legs Syndrome Market Size by Country
6.3.1 North America Restless Legs Syndrome Consumption Value by Country (2021-2032)
6.3.2 United States Restless Legs Syndrome Market Size and Forecast (2021-2032)
6.3.3 Canada Restless Legs Syndrome Market Size and Forecast (2021-2032)
6.3.4 Mexico Restless Legs Syndrome Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Restless Legs Syndrome Consumption Value by Type (2021-2032)
7.2 Europe Restless Legs Syndrome Consumption Value by Application (2021-2032)
7.3 Europe Restless Legs Syndrome Market Size by Country
7.3.1 Europe Restless Legs Syndrome Consumption Value by Country (2021-2032)
7.3.2 Germany Restless Legs Syndrome Market Size and Forecast (2021-2032)
7.3.3 France Restless Legs Syndrome Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Restless Legs Syndrome Market Size and Forecast (2021-2032)
7.3.5 Russia Restless Legs Syndrome Market Size and Forecast (2021-2032)
7.3.6 Italy Restless Legs Syndrome Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Restless Legs Syndrome Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Restless Legs Syndrome Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Restless Legs Syndrome Market Size by Region
8.3.1 Asia-Pacific Restless Legs Syndrome Consumption Value by Region (2021-2032)
8.3.2 China Restless Legs Syndrome Market Size and Forecast (2021-2032)
8.3.3 Japan Restless Legs Syndrome Market Size and Forecast (2021-2032)
8.3.4 South Korea Restless Legs Syndrome Market Size and Forecast (2021-2032)
8.3.5 India Restless Legs Syndrome Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Restless Legs Syndrome Market Size and Forecast (2021-2032)
8.3.7 Australia Restless Legs Syndrome Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Restless Legs Syndrome Consumption Value by Type (2021-2032)
9.2 South America Restless Legs Syndrome Consumption Value by Application (2021-2032)
9.3 South America Restless Legs Syndrome Market Size by Country
9.3.1 South America Restless Legs Syndrome Consumption Value by Country (2021-2032)
9.3.2 Brazil Restless Legs Syndrome Market Size and Forecast (2021-2032)
9.3.3 Argentina Restless Legs Syndrome Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Restless Legs Syndrome Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Restless Legs Syndrome Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Restless Legs Syndrome Market Size by Country
10.3.1 Middle East & Africa Restless Legs Syndrome Consumption Value by Country (2021-2032)
10.3.2 Turkey Restless Legs Syndrome Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Restless Legs Syndrome Market Size and Forecast (2021-2032)
10.3.4 UAE Restless Legs Syndrome Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Restless Legs Syndrome Market Drivers
11.2 Restless Legs Syndrome Market Restraints
11.3 Restless Legs Syndrome Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Restless Legs Syndrome Industry Chain
12.2 Restless Legs Syndrome Upstream Analysis
12.3 Restless Legs Syndrome Midstream Analysis
12.4 Restless Legs Syndrome Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF FIGURES
Table 1. Global Restless Legs Syndrome Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Restless Legs Syndrome Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Restless Legs Syndrome Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Restless Legs Syndrome Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Boehringer Ingelheim GmbH Company Information, Head Office, and Major Competitors
Table 6. Boehringer Ingelheim GmbH Major Business
Table 7. Boehringer Ingelheim GmbH Restless Legs Syndrome Product and Solutions
Table 8. Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Boehringer Ingelheim GmbH Recent Developments and Future Plans
Table 10. UCB SA Company Information, Head Office, and Major Competitors
Table 11. UCB SA Major Business
Table 12. UCB SA Restless Legs Syndrome Product and Solutions
Table 13. UCB SA Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. UCB SA Recent Developments and Future Plans
Table 15. Astellas Company Information, Head Office, and Major Competitors
Table 16. Astellas Major Business
Table 17. Astellas Restless Legs Syndrome Product and Solutions
Table 18. Astellas Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Arbor Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 20. Arbor Pharmaceuticals Major Business
Table 21. Arbor Pharmaceuticals Restless Legs Syndrome Product and Solutions
Table 22. Arbor Pharmaceuticals Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. Arbor Pharmaceuticals Recent Developments and Future Plans
Table 24. GlaxoSmithKline plc. Company Information, Head Office, and Major Competitors
Table 25. GlaxoSmithKline plc. Major Business
Table 26. GlaxoSmithKline plc. Restless Legs Syndrome Product and Solutions
Table 27. GlaxoSmithKline plc. Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. GlaxoSmithKline plc. Recent Developments and Future Plans
Table 29. Ligand Pharmaceuticals Incorporated Company Information, Head Office, and Major Competitors
Table 30. Ligand Pharmaceuticals Incorporated Major Business
Table 31. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product and Solutions
Table 32. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. Ligand Pharmaceuticals Incorporated Recent Developments and Future Plans
Table 34. axxonis Pharma AG Company Information, Head Office, and Major Competitors
Table 35. axxonis Pharma AG Major Business
Table 36. axxonis Pharma AG Restless Legs Syndrome Product and Solutions
Table 37. axxonis Pharma AG Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. axxonis Pharma AG Recent Developments and Future Plans
Table 39. Kyowa Hakko Kirin Co. Company Information, Head Office, and Major Competitors
Table 40. Kyowa Hakko Kirin Co. Major Business
Table 41. Kyowa Hakko Kirin Co. Restless Legs Syndrome Product and Solutions
Table 42. Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. Kyowa Hakko Kirin Co. Recent Developments and Future Plans
Table 44. Jazz Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 45. Jazz Pharmaceuticals, Inc. Major Business
Table 46. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product and Solutions
Table 47. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 48. Jazz Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 49. Omeros Corporation Company Information, Head Office, and Major Competitors
Table 50. Omeros Corporation Major Business
Table 51. Omeros Corporation Restless Legs Syndrome Product and Solutions
Table 52. Omeros Corporation Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 53. Omeros Corporation Recent Developments and Future Plans
Table 54. Manhattan Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 55. Manhattan Pharmaceuticals Major Business
Table 56. Manhattan Pharmaceuticals Restless Legs Syndrome Product and Solutions
Table 57. Manhattan Pharmaceuticals Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 58. Manhattan Pharmaceuticals Recent Developments and Future Plans
Table 59. Global Restless Legs Syndrome Revenue (USD Million) by Players (2021-2026)
Table 60. Global Restless Legs Syndrome Revenue Share by Players (2021-2026)
Table 61. Breakdown of Restless Legs Syndrome by Company Type (Tier 1, Tier 2, and Tier 3)
Table 62. Market Position of Players in Restless Legs Syndrome, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 63. Head Office of Key Restless Legs Syndrome Players
Table 64. Restless Legs Syndrome Market: Company Product Type Footprint
Table 65. Restless Legs Syndrome Market: Company Product Application Footprint
Table 66. Restless Legs Syndrome New Market Entrants and Barriers to Market Entry
Table 67. Restless Legs Syndrome Mergers, Acquisition, Agreements, and Collaborations
Table 68. Global Restless Legs Syndrome Consumption Value (USD Million) by Type (2021-2026)
Table 69. Global Restless Legs Syndrome Consumption Value Share by Type (2021-2026)
Table 70. Global Restless Legs Syndrome Consumption Value Forecast by Type (2027-2032)
Table 71. Global Restless Legs Syndrome Consumption Value by Application (2021-2026)
Table 72. Global Restless Legs Syndrome Consumption Value Forecast by Application (2027-2032)
Table 73. North America Restless Legs Syndrome Consumption Value by Type (2021-2026) & (USD Million)
Table 74. North America Restless Legs Syndrome Consumption Value by Type (2027-2032) & (USD Million)
Table 75. North America Restless Legs Syndrome Consumption Value by Application (2021-2026) & (USD Million)
Table 76. North America Restless Legs Syndrome Consumption Value by Application (2027-2032) & (USD Million)
Table 77. North America Restless Legs Syndrome Consumption Value by Country (2021-2026) & (USD Million)
Table 78. North America Restless Legs Syndrome Consumption Value by Country (2027-2032) & (USD Million)
Table 79. Europe Restless Legs Syndrome Consumption Value by Type (2021-2026) & (USD Million)
Table 80. Europe Restless Legs Syndrome Consumption Value by Type (2027-2032) & (USD Million)
Table 81. Europe Restless Legs Syndrome Consumption Value by Application (2021-2026) & (USD Million)
Table 82. Europe Restless Legs Syndrome Consumption Value by Application (2027-2032) & (USD Million)
Table 83. Europe Restless Legs Syndrome Consumption Value by Country (2021-2026) & (USD Million)
Table 84. Europe Restless Legs Syndrome Consumption Value by Country (2027-2032) & (USD Million)
Table 85. Asia-Pacific Restless Legs Syndrome Consumption Value by Type (2021-2026) & (USD Million)
Table 86. Asia-Pacific Restless Legs Syndrome Consumption Value by Type (2027-2032) & (USD Million)
Table 87. Asia-Pacific Restless Legs Syndrome Consumption Value by Application (2021-2026) & (USD Million)
Table 88. Asia-Pacific Restless Legs Syndrome Consumption Value by Application (2027-2032) & (USD Million)
Table 89. Asia-Pacific Restless Legs Syndrome Consumption Value by Region (2021-2026) & (USD Million)
Table 90. Asia-Pacific Restless Legs Syndrome Consumption Value by Region (2027-2032) & (USD Million)
Table 91. South America Restless Legs Syndrome Consumption Value by Type (2021-2026) & (USD Million)
Table 92. South America Restless Legs Syndrome Consumption Value by Type (2027-2032) & (USD Million)
Table 93. South America Restless Legs Syndrome Consumption Value by Application (2021-2026) & (USD Million)
Table 94. South America Restless Legs Syndrome Consumption Value by Application (2027-2032) & (USD Million)
Table 95. South America Restless Legs Syndrome Consumption Value by Country (2021-2026) & (USD Million)
Table 96. South America Restless Legs Syndrome Consumption Value by Country (2027-2032) & (USD Million)
Table 97. Middle East & Africa Restless Legs Syndrome Consumption Value by Type (2021-2026) & (USD Million)
Table 98. Middle East & Africa Restless Legs Syndrome Consumption Value by Type (2027-2032) & (USD Million)
Table 99. Middle East & Africa Restless Legs Syndrome Consumption Value by Application (2021-2026) & (USD Million)
Table 100. Middle East & Africa Restless Legs Syndrome Consumption Value by Application (2027-2032) & (USD Million)
Table 101. Middle East & Africa Restless Legs Syndrome Consumption Value by Country (2021-2026) & (USD Million)
Table 102. Middle East & Africa Restless Legs Syndrome Consumption Value by Country (2027-2032) & (USD Million)
Table 103. Global Key Players of Restless Legs Syndrome Upstream (Raw Materials)
Table 104. Global Restless Legs Syndrome Typical Customers
LIST OF FIGURES
Figure 1. Restless Legs Syndrome Picture
Figure 2. Global Restless Legs Syndrome Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Restless Legs Syndrome Consumption Value Market Share by Type in 2025
Figure 4. Pharmacological Therapy
Figure 5. Non-Pharmacological Therapy
Figure 6. Global Restless Legs Syndrome Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 7. Restless Legs Syndrome Consumption Value Market Share by Application in 2025
Figure 8. Below 35 Years Old Picture
Figure 9. From 35 to 50 Years Old Picture
Figure 10. Above 50 Years Old Picture
Figure 11. Global Restless Legs Syndrome Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 12. Global Restless Legs Syndrome Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 13. Global Market Restless Legs Syndrome Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 14. Global Restless Legs Syndrome Consumption Value Market Share by Region (2021-2032)
Figure 15. Global Restless Legs Syndrome Consumption Value Market Share by Region in 2025
Figure 16. North America Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 17. Europe Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 18. Asia-Pacific Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 19. South America Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 20. Middle East & Africa Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 21. Company Three Recent Developments and Future Plans
Figure 22. Global Restless Legs Syndrome Revenue Share by Players in 2025
Figure 23. Restless Legs Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 24. Market Share of Restless Legs Syndrome by Player Revenue in 2025
Figure 25. Top 3 Restless Legs Syndrome Players Market Share in 2025
Figure 26. Top 6 Restless Legs Syndrome Players Market Share in 2025
Figure 27. Global Restless Legs Syndrome Consumption Value Share by Type (2021-2026)
Figure 28. Global Restless Legs Syndrome Market Share Forecast by Type (2027-2032)
Figure 29. Global Restless Legs Syndrome Consumption Value Share by Application (2021-2026)
Figure 30. Global Restless Legs Syndrome Market Share Forecast by Application (2027-2032)
Figure 31. North America Restless Legs Syndrome Consumption Value Market Share by Type (2021-2032)
Figure 32. North America Restless Legs Syndrome Consumption Value Market Share by Application (2021-2032)
Figure 33. North America Restless Legs Syndrome Consumption Value Market Share by Country (2021-2032)
Figure 34. United States Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 35. Canada Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 36. Mexico Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 37. Europe Restless Legs Syndrome Consumption Value Market Share by Type (2021-2032)
Figure 38. Europe Restless Legs Syndrome Consumption Value Market Share by Application (2021-2032)
Figure 39. Europe Restless Legs Syndrome Consumption Value Market Share by Country (2021-2032)
Figure 40. Germany Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 41. France Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 42. United Kingdom Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 43. Russia Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 44. Italy Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 45. Asia-Pacific Restless Legs Syndrome Consumption Value Market Share by Type (2021-2032)
Figure 46. Asia-Pacific Restless Legs Syndrome Consumption Value Market Share by Application (2021-2032)
Figure 47. Asia-Pacific Restless Legs Syndrome Consumption Value Market Share by Region (2021-2032)
Figure 48. China Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 49. Japan Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 50. South Korea Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 51. India Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 52. Southeast Asia Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 53. Australia Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 54. South America Restless Legs Syndrome Consumption Value Market Share by Type (2021-2032)
Figure 55. South America Restless Legs Syndrome Consumption Value Market Share by Application (2021-2032)
Figure 56. South America Restless Legs Syndrome Consumption Value Market Share by Country (2021-2032)
Figure 57. Brazil Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 58. Argentina Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 59. Middle East & Africa Restless Legs Syndrome Consumption Value Market Share by Type (2021-2032)
Figure 60. Middle East & Africa Restless Legs Syndrome Consumption Value Market Share by Application (2021-2032)
Figure 61. Middle East & Africa Restless Legs Syndrome Consumption Value Market Share by Country (2021-2032)
Figure 62. Turkey Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 63. Saudi Arabia Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 64. UAE Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 65. Restless Legs Syndrome Market Drivers
Figure 66. Restless Legs Syndrome Market Restraints
Figure 67. Restless Legs Syndrome Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Restless Legs Syndrome Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
Table 1. Global Restless Legs Syndrome Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Restless Legs Syndrome Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Restless Legs Syndrome Consumption Value by Region (2021-2026) & (USD Million)
Table 4. Global Restless Legs Syndrome Consumption Value by Region (2027-2032) & (USD Million)
Table 5. Boehringer Ingelheim GmbH Company Information, Head Office, and Major Competitors
Table 6. Boehringer Ingelheim GmbH Major Business
Table 7. Boehringer Ingelheim GmbH Restless Legs Syndrome Product and Solutions
Table 8. Boehringer Ingelheim GmbH Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Boehringer Ingelheim GmbH Recent Developments and Future Plans
Table 10. UCB SA Company Information, Head Office, and Major Competitors
Table 11. UCB SA Major Business
Table 12. UCB SA Restless Legs Syndrome Product and Solutions
Table 13. UCB SA Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. UCB SA Recent Developments and Future Plans
Table 15. Astellas Company Information, Head Office, and Major Competitors
Table 16. Astellas Major Business
Table 17. Astellas Restless Legs Syndrome Product and Solutions
Table 18. Astellas Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Arbor Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 20. Arbor Pharmaceuticals Major Business
Table 21. Arbor Pharmaceuticals Restless Legs Syndrome Product and Solutions
Table 22. Arbor Pharmaceuticals Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 23. Arbor Pharmaceuticals Recent Developments and Future Plans
Table 24. GlaxoSmithKline plc. Company Information, Head Office, and Major Competitors
Table 25. GlaxoSmithKline plc. Major Business
Table 26. GlaxoSmithKline plc. Restless Legs Syndrome Product and Solutions
Table 27. GlaxoSmithKline plc. Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 28. GlaxoSmithKline plc. Recent Developments and Future Plans
Table 29. Ligand Pharmaceuticals Incorporated Company Information, Head Office, and Major Competitors
Table 30. Ligand Pharmaceuticals Incorporated Major Business
Table 31. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product and Solutions
Table 32. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 33. Ligand Pharmaceuticals Incorporated Recent Developments and Future Plans
Table 34. axxonis Pharma AG Company Information, Head Office, and Major Competitors
Table 35. axxonis Pharma AG Major Business
Table 36. axxonis Pharma AG Restless Legs Syndrome Product and Solutions
Table 37. axxonis Pharma AG Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 38. axxonis Pharma AG Recent Developments and Future Plans
Table 39. Kyowa Hakko Kirin Co. Company Information, Head Office, and Major Competitors
Table 40. Kyowa Hakko Kirin Co. Major Business
Table 41. Kyowa Hakko Kirin Co. Restless Legs Syndrome Product and Solutions
Table 42. Kyowa Hakko Kirin Co. Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 43. Kyowa Hakko Kirin Co. Recent Developments and Future Plans
Table 44. Jazz Pharmaceuticals, Inc. Company Information, Head Office, and Major Competitors
Table 45. Jazz Pharmaceuticals, Inc. Major Business
Table 46. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product and Solutions
Table 47. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 48. Jazz Pharmaceuticals, Inc. Recent Developments and Future Plans
Table 49. Omeros Corporation Company Information, Head Office, and Major Competitors
Table 50. Omeros Corporation Major Business
Table 51. Omeros Corporation Restless Legs Syndrome Product and Solutions
Table 52. Omeros Corporation Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 53. Omeros Corporation Recent Developments and Future Plans
Table 54. Manhattan Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 55. Manhattan Pharmaceuticals Major Business
Table 56. Manhattan Pharmaceuticals Restless Legs Syndrome Product and Solutions
Table 57. Manhattan Pharmaceuticals Restless Legs Syndrome Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 58. Manhattan Pharmaceuticals Recent Developments and Future Plans
Table 59. Global Restless Legs Syndrome Revenue (USD Million) by Players (2021-2026)
Table 60. Global Restless Legs Syndrome Revenue Share by Players (2021-2026)
Table 61. Breakdown of Restless Legs Syndrome by Company Type (Tier 1, Tier 2, and Tier 3)
Table 62. Market Position of Players in Restless Legs Syndrome, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 63. Head Office of Key Restless Legs Syndrome Players
Table 64. Restless Legs Syndrome Market: Company Product Type Footprint
Table 65. Restless Legs Syndrome Market: Company Product Application Footprint
Table 66. Restless Legs Syndrome New Market Entrants and Barriers to Market Entry
Table 67. Restless Legs Syndrome Mergers, Acquisition, Agreements, and Collaborations
Table 68. Global Restless Legs Syndrome Consumption Value (USD Million) by Type (2021-2026)
Table 69. Global Restless Legs Syndrome Consumption Value Share by Type (2021-2026)
Table 70. Global Restless Legs Syndrome Consumption Value Forecast by Type (2027-2032)
Table 71. Global Restless Legs Syndrome Consumption Value by Application (2021-2026)
Table 72. Global Restless Legs Syndrome Consumption Value Forecast by Application (2027-2032)
Table 73. North America Restless Legs Syndrome Consumption Value by Type (2021-2026) & (USD Million)
Table 74. North America Restless Legs Syndrome Consumption Value by Type (2027-2032) & (USD Million)
Table 75. North America Restless Legs Syndrome Consumption Value by Application (2021-2026) & (USD Million)
Table 76. North America Restless Legs Syndrome Consumption Value by Application (2027-2032) & (USD Million)
Table 77. North America Restless Legs Syndrome Consumption Value by Country (2021-2026) & (USD Million)
Table 78. North America Restless Legs Syndrome Consumption Value by Country (2027-2032) & (USD Million)
Table 79. Europe Restless Legs Syndrome Consumption Value by Type (2021-2026) & (USD Million)
Table 80. Europe Restless Legs Syndrome Consumption Value by Type (2027-2032) & (USD Million)
Table 81. Europe Restless Legs Syndrome Consumption Value by Application (2021-2026) & (USD Million)
Table 82. Europe Restless Legs Syndrome Consumption Value by Application (2027-2032) & (USD Million)
Table 83. Europe Restless Legs Syndrome Consumption Value by Country (2021-2026) & (USD Million)
Table 84. Europe Restless Legs Syndrome Consumption Value by Country (2027-2032) & (USD Million)
Table 85. Asia-Pacific Restless Legs Syndrome Consumption Value by Type (2021-2026) & (USD Million)
Table 86. Asia-Pacific Restless Legs Syndrome Consumption Value by Type (2027-2032) & (USD Million)
Table 87. Asia-Pacific Restless Legs Syndrome Consumption Value by Application (2021-2026) & (USD Million)
Table 88. Asia-Pacific Restless Legs Syndrome Consumption Value by Application (2027-2032) & (USD Million)
Table 89. Asia-Pacific Restless Legs Syndrome Consumption Value by Region (2021-2026) & (USD Million)
Table 90. Asia-Pacific Restless Legs Syndrome Consumption Value by Region (2027-2032) & (USD Million)
Table 91. South America Restless Legs Syndrome Consumption Value by Type (2021-2026) & (USD Million)
Table 92. South America Restless Legs Syndrome Consumption Value by Type (2027-2032) & (USD Million)
Table 93. South America Restless Legs Syndrome Consumption Value by Application (2021-2026) & (USD Million)
Table 94. South America Restless Legs Syndrome Consumption Value by Application (2027-2032) & (USD Million)
Table 95. South America Restless Legs Syndrome Consumption Value by Country (2021-2026) & (USD Million)
Table 96. South America Restless Legs Syndrome Consumption Value by Country (2027-2032) & (USD Million)
Table 97. Middle East & Africa Restless Legs Syndrome Consumption Value by Type (2021-2026) & (USD Million)
Table 98. Middle East & Africa Restless Legs Syndrome Consumption Value by Type (2027-2032) & (USD Million)
Table 99. Middle East & Africa Restless Legs Syndrome Consumption Value by Application (2021-2026) & (USD Million)
Table 100. Middle East & Africa Restless Legs Syndrome Consumption Value by Application (2027-2032) & (USD Million)
Table 101. Middle East & Africa Restless Legs Syndrome Consumption Value by Country (2021-2026) & (USD Million)
Table 102. Middle East & Africa Restless Legs Syndrome Consumption Value by Country (2027-2032) & (USD Million)
Table 103. Global Key Players of Restless Legs Syndrome Upstream (Raw Materials)
Table 104. Global Restless Legs Syndrome Typical Customers
LIST OF FIGURES
Figure 1. Restless Legs Syndrome Picture
Figure 2. Global Restless Legs Syndrome Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Restless Legs Syndrome Consumption Value Market Share by Type in 2025
Figure 4. Pharmacological Therapy
Figure 5. Non-Pharmacological Therapy
Figure 6. Global Restless Legs Syndrome Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 7. Restless Legs Syndrome Consumption Value Market Share by Application in 2025
Figure 8. Below 35 Years Old Picture
Figure 9. From 35 to 50 Years Old Picture
Figure 10. Above 50 Years Old Picture
Figure 11. Global Restless Legs Syndrome Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 12. Global Restless Legs Syndrome Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 13. Global Market Restless Legs Syndrome Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 14. Global Restless Legs Syndrome Consumption Value Market Share by Region (2021-2032)
Figure 15. Global Restless Legs Syndrome Consumption Value Market Share by Region in 2025
Figure 16. North America Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 17. Europe Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 18. Asia-Pacific Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 19. South America Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 20. Middle East & Africa Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 21. Company Three Recent Developments and Future Plans
Figure 22. Global Restless Legs Syndrome Revenue Share by Players in 2025
Figure 23. Restless Legs Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 24. Market Share of Restless Legs Syndrome by Player Revenue in 2025
Figure 25. Top 3 Restless Legs Syndrome Players Market Share in 2025
Figure 26. Top 6 Restless Legs Syndrome Players Market Share in 2025
Figure 27. Global Restless Legs Syndrome Consumption Value Share by Type (2021-2026)
Figure 28. Global Restless Legs Syndrome Market Share Forecast by Type (2027-2032)
Figure 29. Global Restless Legs Syndrome Consumption Value Share by Application (2021-2026)
Figure 30. Global Restless Legs Syndrome Market Share Forecast by Application (2027-2032)
Figure 31. North America Restless Legs Syndrome Consumption Value Market Share by Type (2021-2032)
Figure 32. North America Restless Legs Syndrome Consumption Value Market Share by Application (2021-2032)
Figure 33. North America Restless Legs Syndrome Consumption Value Market Share by Country (2021-2032)
Figure 34. United States Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 35. Canada Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 36. Mexico Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 37. Europe Restless Legs Syndrome Consumption Value Market Share by Type (2021-2032)
Figure 38. Europe Restless Legs Syndrome Consumption Value Market Share by Application (2021-2032)
Figure 39. Europe Restless Legs Syndrome Consumption Value Market Share by Country (2021-2032)
Figure 40. Germany Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 41. France Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 42. United Kingdom Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 43. Russia Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 44. Italy Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 45. Asia-Pacific Restless Legs Syndrome Consumption Value Market Share by Type (2021-2032)
Figure 46. Asia-Pacific Restless Legs Syndrome Consumption Value Market Share by Application (2021-2032)
Figure 47. Asia-Pacific Restless Legs Syndrome Consumption Value Market Share by Region (2021-2032)
Figure 48. China Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 49. Japan Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 50. South Korea Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 51. India Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 52. Southeast Asia Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 53. Australia Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 54. South America Restless Legs Syndrome Consumption Value Market Share by Type (2021-2032)
Figure 55. South America Restless Legs Syndrome Consumption Value Market Share by Application (2021-2032)
Figure 56. South America Restless Legs Syndrome Consumption Value Market Share by Country (2021-2032)
Figure 57. Brazil Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 58. Argentina Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 59. Middle East & Africa Restless Legs Syndrome Consumption Value Market Share by Type (2021-2032)
Figure 60. Middle East & Africa Restless Legs Syndrome Consumption Value Market Share by Application (2021-2032)
Figure 61. Middle East & Africa Restless Legs Syndrome Consumption Value Market Share by Country (2021-2032)
Figure 62. Turkey Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 63. Saudi Arabia Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 64. UAE Restless Legs Syndrome Consumption Value (2021-2032) & (USD Million)
Figure 65. Restless Legs Syndrome Market Drivers
Figure 66. Restless Legs Syndrome Market Restraints
Figure 67. Restless Legs Syndrome Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Restless Legs Syndrome Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
